Cynata OTC Stock Today

CYYNF -  USA Stock  

USD 0.40  0.00  0.00%

Cynata Therapeutics is trading at 0.4 as of the 28th of November 2021, a No Change since the beginning of the trading day. The stock's lowest day price was 0.4. Cynata Therapeutics has more than 61 % chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. Equity ratings for Cynata Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of December 2019 and ending today, the 28th of November 2021. Click here to learn more.
Market Performance
12 of 100
Odds Of Distress
Over 61
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. Cynata Therapeutics Limited was founded in 2011 and is based in Cremorne, Australia. The company has 95.66 M outstanding shares. More on Cynata Therapeutics

Cynata Therapeutics OTC Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Cynata Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Cynata Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Cynata Therapeutics has some characteristics of a very speculative penny stock
Cynata Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the revenue of 1.55 M. Net Loss for the year was (7.69 M) with profit before overhead, payroll, taxes, and interest of 1.55 M.
Cynata Therapeutics has accumulated about 26.72 M in cash with (5.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.19.
Roughly 14.0% of the company shares are held by company insiders
Latest headline from www.marketscreener.com: Cynata Therapeutics AGM Presentations - marketscreener.com
Legal NameCynata Therapeutics
CEORoss Macdonald  (View All)
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Cynata Therapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldOvervalued
Cynata Therapeutics [CYYNF] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Micro-Cap' category with current market capitalization of 37.74 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cynata Therapeutics's market, we take the total number of its shares issued and multiply it by Cynata Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Cynata Therapeutics has 95.66 M outstanding shares. Cynata Therapeutics has accumulated about 26.72 M in cash with (5.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.19.
Check Cynata Therapeutics Probability Of Bankruptcy
Ownership
Cynata Therapeutics holds a total of ninety-five million six hundred sixty thousand outstanding shares. Cynata Therapeutics shows 14.18 percent if its outstanding shares held by insiders and 14.18 percent owned by other corporate entities . Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Cynata Ownership Details

Cynata Stock Price Odds Analysis

What are Cynata Therapeutics' target price odds to finish over the current price? Based on a normal probability distribution, the odds of Cynata Therapeutics jumping above the current price in 90 days from now is about 14.63%. The Cynata Therapeutics probability density function shows the probability of Cynata Therapeutics otc stock to fall within a particular range of prices over 90 days. Assuming the 90 days horizon Cynata Therapeutics has a beta of -0.1243 suggesting as returns on benchmark increase, returns on holding Cynata Therapeutics are expected to decrease at a much lower rate. During the bear market, however, Cynata Therapeutics is likely to outperform the market. Additionally, the company has an alpha of 0.2929, implying that it can generate a 0.29 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Odds Down 0.4HorizonTargetOdds Up 0.4 
85.27%90 days
 0.40 
14.63%
Based on a normal probability distribution, the odds of Cynata Therapeutics to move above the current price in 90 days from now is about 14.63 (This Cynata Therapeutics probability density function shows the probability of Cynata OTC Stock to fall within a particular range of prices over 90 days) .

Cynata Therapeutics Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Cynata Therapeutics market risk premium is the additional return an investor will receive from holding Cynata Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cynata Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Cynata Therapeutics' alpha and beta are two of the key measurements used to evaluate Cynata Therapeutics' performance over the market, the standard measures of volatility play an important role as well.

Cynata Stock Against Markets

Picking the right benchmark for Cynata Therapeutics otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Cynata Therapeutics otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Cynata Therapeutics is critical whether you are bullish or bearish towards Cynata Therapeutics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Cynata Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Manager Now

   

Portfolio Manager

State of the art Portfolio Manager to monitor and improve performance of your invested capital
All  Next Launch Module

Cynata Therapeutics Corporate Directors

Cynata Therapeutics corporate directors refer to members of a Cynata Therapeutics board of directors. The board of directors generally takes responsibility for the Cynata Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Cynata Therapeutics' board members must vote for the resolution. The Cynata Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Geoffrey Brooke - Independent Non-Executive DirectorProfile
Peter Webse - Company Secretary, Non-Executive DirectorProfile
John Chiplin - Non-Executive Independent DirectorProfile
Paul Wotton - DirectorProfile
Continue to Trending Equities. Note that the Cynata Therapeutics information on this page should be used as a complementary analysis to other Cynata Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try CEO Directory module to screen CEOs from public companies around the world.

Complementary Tools for Cynata OTC Stock analysis

When running Cynata Therapeutics price analysis, check to measure Cynata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cynata Therapeutics is operating at the current time. Most of Cynata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cynata Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cynata Therapeutics' price. Additionally, you may evaluate how the addition of Cynata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Is Cynata Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cynata Therapeutics. If investors know Cynata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cynata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cynata Therapeutics is measured differently than its book value, which is the value of Cynata that is recorded on the company's balance sheet. Investors also form their own opinion of Cynata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cynata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cynata Therapeutics' market value can be influenced by many factors that don't directly affect Cynata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cynata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cynata Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cynata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.